According to the US EPA’s Office of Inspector General (OIG), approximately 300 chemicals considered by the Resource Conservation and Recovery Act to be hazardous are unregulated. The Clean Water Act allows the EPA to regulate any substances, but the agency applies the rule to only 126 priority chemicals. Although industrial polluters are required to report […]
A summary of biopharmaceutical approvals in the US and UK from January 2010 to July 2014 showed that 54 products were approved. Drugs new to the market accounted for 59% of the therapies (32), with the remaining biologics being biosimilars, reformulated and me-too drugs, and products that previously had been approved elsewhere. Of the 32 […]
Company Announcements For the fiscal first quarter ending June 30, Hitachi High-Technologies Science and Medical Systems (SMS) sales climbed 33% to ¥38.8 billion ($380.1 million = ¥102.09 = $1) to account for 25% of company revenues (see IBO 7/31/14). Medical product sales jumped 53%, and sales of Biotechnology and Other products grew 16% to account […]
The US Congress has passed a spending bill to keep the federal government in operation from October 1, the beginning of the new fiscal year, to December 11, after November’s congressional elections. Budgets for the NIH, NSF, DOE, FDA and EPA were maintained at fiscal 2014 levels. However, the CDC received an additional $30 million […]
The FDA has announced revisions to four areas of its proposed rules for implementation of the Food Safety Modernization Act. For the rule on produce safety, the proposed revision includes water-quality–testing requirements for produce safety, including an updated microbial-quality standard, greater flexibility for compliance with the microbial standard, and a more targeted approach to testing […]
R&D spending by oil companies is at risk as firms cut costs. Critics argue that the cuts come at the time when investment is most needed in order to maintain current growth using new technologies and to develop alternative energy. Among large oil firms, Royal Dutch Shell and Total spent the most on R&D in […]
The UK government made public this month a third-party final report reviewing the country’s food-supply networks and their response to food adulteration in light of the 2013 EU horse-meat incident, when beef products were found to contain horse meat and other products from animals besides cow (see IBO 2/15/13). The government also published a response […]
The Grocery Manufacturers Association (GMA), a trade group representing over 300 companies in the food, beverage, and consumer-products industry, announced last month its plans to address consumer concerns about food additives that are “Generally Recognized as Safe” (GRAS). Currently, companies can decide if a substance is GRAS without approval by the FDA. Per the GMA’s […]
The first US application for a biosimilar, a generic version of Amgen’s Neupogen, was submitted to the FDA in July by Novartis. So far, the FDA has had 59 meetings with companies to discuss 14 biosimilars. Biosimilars are expected to provide a 30% discount to the price of biologics. Source: BusinessWeek
In their July survey of 958 chemical companies, ICIS and Genomatica found that over the last year, chemical producers have experienced the same level (44%) or greater (36%) interest in sustainable chemicals from their customers. More sustainable versions of chemicals are already offered by 31% of producers, with 41% expecting to offer them within the […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
